Kymera Therapeutics (KYMR) News
NASDAQ: KYMRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
112.40+3.10 (+2.84%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
KYMR news summary
We found 2 recent headlines mentioning Kymera Therapeutics (KYMR): 1 in the past week and 1 in the past 30 days, most often from Nasdaq. For price context, KYMR is up 2.84% at $112.40. The most recent story, "Raymond James Initiates Coverage of Kymera Therapeutics with Outperform Rating", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Kymera Therapeutics headlines
- Raymond James Initiates Coverage of Kymera Therapeutics with Outperform RatingFintel reports that on October 9, 2026, Raymond James initiated coverage of Kymera Therapeutics (NASDAQGM:KYMR) with a Outperform recommendation. Prior to this rating action, the stock closed at…Nasdaq
- Kymera Appoints Felix Baker As Board Chairman, Succeeds Bruce Booth(RTTNews) - Kymera Therapeutics, Inc. (KYMR), a clinical-stage biopharmaceutical company, announced the appointment of Felix J. Baker as Chairman of the Board of Directors. He succeeds Bruce Booth,…NasdaqBCYC, KNSA, KOD, KYMR